Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pramipexole (SND 919) is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
500 mg | In stock | $ 42.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 46.00 |
Description | Pramipexole (SND 919) is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury. |
Targets&IC50 | D2S receptor:3.9 nM(Ki), D4 receptor:5.1 nM(Ki), D2L receptor:2.2 nM(Ki), D3 receptor:0.5 nM(Ki) |
Synonyms | SND 919 |
Molecular Weight | 211.33 |
Formula | C10H17N3S |
CAS No. | 104632-26-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 39 mg/mL (184.5 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 39 mg/mL (184.5 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pramipexole 104632-26-0 GPCR/G Protein Neuroscience Dopamine Receptor disease Parkinson's artery SND 919 SND-919 syndrome occlusion RLS recovery neuroprotection transient inhibit middle neurological SND919 restless cerebral tMCAO Inhibitor legs inhibitor